SRH Wald-Klinikum Gera

Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry (2022) Mohr P, Scherrer E, Alar V, Assaf C, Beissert S, Berking C, Eigentler T, et al. Conference contribution Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry (2022) Laakmann E, Witzel I, Neunhoeffer T, Park-Simon TW, Weide R, Riecke K, Polasik A, et al. Journal article Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity (2022) Koch E, Petzold A, Wessely A, Dippel E, Gesierich A, Gutzmer R, Hassel JC, et al. Journal article Clinical Prognostic Factors in metastatic Choroidal Melanoma (2021) Koch E, Petzold A, Wessely A, Dippel E, Erdmann M, Heinzerling L, Hohberger B, et al. Conference contribution A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer (2021) Hecht M, Hahn D, Wolber P, Hautmann MG, Reichert D, Weniger S, Belka C, et al. Journal article Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis (2021) Koch E, Petzold A, Wessely A, Dippel E, Gesierich A, Gutzmer R, Hassel JC, et al. Journal article Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study (2021) Kaehler KC, Gutzmer R, Meier F, Zimmer L, Heppt M, Gesierich A, Thoms KM, et al. Journal article Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto (2021) Labidi-Galy SI, Schneeweiss A, Sinn HP, Blohmer JU, Romanens L, Zahm DM, Huober J, et al. Conference contribution Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial (2021) Llop-Guevara A, Vladimirova V, Schneeweiss A, Villacampa G, Karn T, Zahm DM, Herencia-Ropero A, et al. Journal article, Original article Immune-related gene expression predicts response to neoadjuvant chemotherapy but not additional benefit from pd-l1 inhibition in women with early triple-negative breast cancer (2021) Sinn BV, Loibl S, Hanusch CA, Zahm DM, Sinn HP, Untch M, Weber K, et al. Journal article